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Abstract Recently, plasmid-mediated and, therefore, transfer-
able bacterial polymyxin resistance was discovered in strains
from both humans and animals. Such a trait may widely spread
geographically, while simultaneously crossingmicrobial species
barriers. This may ultimately render the Blast resort^ polymyxin
antibiotics therapeutically useless. Colistin is currently used to
treat infections caused by Gram-negative carbapenemase pro-
ducers and colistin resistance may lead to practical pan-
antibiotic resistance.We here analyzed themedical and diagnos-
tic consequences of (emerging) colistin resistance and propose
pathways toward adequate diagnostics for timely detection of
both asymptomatic carriage and infection. Culture-based testing
using chromogenic and selective media for screening clinical
(and veterinary) specimens may constitute key tools for that
purpose. Relevant molecular tests are also discussed.
What is colistin?
Colistin, also known as polymyxin E, is produced by
Paenibacillus polymyxa and belongs to the polymyxin class
of antibiotics. It is a polycationic peptide with both
hydrophilic and lipophilic domains. The cationic regions in-
teract with bacterial lipopolysaccharide (LPS) in the outer cell
membrane, where it displaces magnesium and calcium coun-
ter ions. Colistin is not homogeneous at the molecular level
and consists of a mix of the cyclic polypeptides A and B.
Colistin essentially solubilizes the bacterial cell membrane,
which is bactericidal in an aqueous environment. It is an older
drug with significant nephrotoxicity.
Colistin is commonly used in agriculture in many countries
for the control of infections in pigs and, in particular, cattle. Its
usage in humans was, so far, rather limited, mainly because of
its renal toxicity, but it has been recently re-introduced as a
last-line option to treat extensively antibiotic-resistant bacteria
such as carbapenem-resistant strains [i.e., NDM-1- and KPC-
positive bacterial isolates or extensively drug-resistant (XDR)
Acinetobacter baumannii and Pseudomonas aeruginosa].
Colistin has been effective in treating infections caused by
P. aeruginosa, Escherichia coli, andKlebsiella spp., for which
the range of Bnormal^ minimum inhibitory concentrations
(MICs) is ≤0.06–4 μg/ml, 0.12–2 μg/ml, and 0.25–2 μg/ml
for their wild-type populations, respectively. Colistin is also
used for (a) prophylactic and selective decontamination of the
digestive tract in intensive care unit (ICU) patients and (b)
reducing respiratory tract infections [1]. BClassical^ resistance
to colistin is rare. However, the SENTRY surveillance net-
work detected colistin resistance associated with the presence
of the plasmid-mediated colistin resistance mechanism, in-
volving the mcr-1 gene, among E. coli and K. pneumoniae
during 2014–2015 [2–4].
Classical colistin resistance
Antibiotic susceptibility testing (AST) is normally performed
using highly standardized microbiological technology and, in
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the case of colistin, the most common protocol has been joint-
ly endorsed by both the Clinical & Laboratory Standards
Institute (CLSI) and the European Committee on
Antimicrobial Susceptibility Testing (EUCAST), the
American and European groups overseeing standardization
of AST laboratory protocols. Measurement of exact colistin
MICs is associated with methodological issues, but the ISO-
standard broth microdilution (BMD) method (20776-1) works
well for Enterobacteriaceae, P. aeruginosa, and Acinetobacter
spp. Specifically, additive-free cation-supplemented Mueller–
Hinton broth needs to be employed. Trays must be made of
plain polystyrene and not treated in any way before use,
whereas sulfate salts of the antibiotic work best.
Susceptibility testing by other methods, including agar dilu-
tion, disk diffusion, and gradient diffusion, cannot be recom-
mended in the absence of regional historical colistin MIC data
as a reference. Newer methods including the molecular ones
are still in need of optimization.
Classical resistance to colistin can be explained by a variety
of mechanisms. In E. coli, Salmonella enterica [3],
K. pneumoniae, and P. aeruginosa, the net LPS charge can be
reduced uponmodification of lipid A through the chemical cou-
pling of phosphoethanolamine or L-amino-arabinose through
activation of the pmrC or pmrF operons. Also, the presence of
a capsule has been shown to interfere with polymyxin suscepti-
bility in K. pneumoniae. Resistance to colistin in A. baumannii
may be associated with mutations in the PmrAB two-
component system or with a progressive to full loss of LPS
through mutations in the lpxA, lpxC, and lpxD genes [5]. A
single mutation in the PmrB protein, which is a sensor kinase,
can lead to the addition of phosphoethanolamine to lipid A,
which causes high-level colistin resistance in A. baumannii.
Studies in P. aeruginosa also suggested a potential role in the
resistance to polymyxins for OprH, an outer membrane protein
contributing tomembrane stability [6].Multidrug efflux systems
can also be responsible for polymyxin resistance in
P. aeruginosa [7]. Changes in the regulatory loci pmrA and
phoP have also been shown to be responsible for polymyxin
resistance in Enterobacteriaceae. With time, additional novel
resistance mechanisms will be identified. Until very recently,
colistin resistance was always thought to be chromosomally
encoded allowing vertical transmission only. In addition, this
type of resistance often appears to be quite unstable, self-limit-
ing, and does not prevent the successful use of polymyxins.
Emerging mobile colistin resistance markers
In late 2015, a plasmid-borne mcr-1 gene encoding a
phosphoethanolamine transferase giving rise to polymyxin
resistance was first identified in bacterial strains of animal
origin, but also in those cultured from humans and the envi-
ronment [8]. The plasmid localization of that resistance trait
allows for horizontal transmission of the colistin resistance.
Surveillance of E. coli strains from food animals in China
showed that the plasmid was present in 15 % of strains found
in meat samples and in 21 % of strains derived directly from
animals. It was documented that the strains emerged locally
between 2012 and 2014. MCR-1-producing E. coli and
K. pneumoniae strains were detected in blood and urine spec-
imens from hospitalized patients, showing that host species
barriers had already been crossed by the plasmid. In addition,
all strains were extended-spectrum β-lactamase (ESBL) pro-
ducers [8] and similar strains were isolated from outpatients as
well [9].
Transferable colistin resistance has been detected in 10 % of
NDM-1-producing carbapenem-resistant Enterobacteriaceae
(CRE) in the United Kingdom [10]. In Italy, the proportion of
colistin resistance among KPC-producing K. pneumoniae was
57 % in 2013 [11]. Following these important findings, several
international teams started looking for this new gene in existing
collections of bacteria. In January 2016, mcr-1-positive strains
were already found in about 19 different countries, including
Malaysia [7], France [12, 13], Portugal [14], Laos [15], USA,
Thailand, Algeria [16, 17], Germany [18], Switzerland [19, 20],
Japan, Belgium, Vietnam [21, 22], the Netherlands [23], Spain
[24], and Denmark [25]. The frequency of occurrence ofmcr-1-
positive bacterial isolates still seems relatively low in humans: in
China, 1.4 % of the E. coli strains and 0.7 % of the
K. pneumoniae isolates scored phenotypically positive. In
Europe (Denmark), 0.2 % of the ESBL- and AmpC-positive
E. coli strains aremcr-1 PCR-positive. In animals, the detection
of mcr-1 was lower in Europe than in China, with 15 % of
detection in the latter country compared to 1.5 % in the
Netherlands and 2 % in Denmark [26].
In bacterial strains from humans, transferable colistin resis-
tance was mainly identified in isolates from patients who were
not treated with colistin, and it has been speculated that acqui-
sition of such resistant strains might have resulted from the
ingestion of contaminated meat, leading to asymptomatic gas-
trointestinal colonization [25]. Currently, mcr-1 has been
found in E. coli, K. pneumoniae, and Salmonella, and could
be successfully maintained in P. aeruginosa [8]. Although
many mcr-1-positive isolates were shown to co-produce an
ESBL enzyme, it is noteworthy that many mcr-1-producing
E. coli isolates are fully susceptible to β-lactams and are,
therefore, far from multidrug-resistant [13, 23, 25].
Nevertheless, there have been reports of mcr-1-producing
mul t id rug- res i s tan t i so la tes , and , in par t icu la r,
carbapenemase-producing ones. The first identified isolate
was a VIM-1-producing E. coli recovered in Switzerland from
a patient who did not have any history of foreign travel [19].
That isolate remained susceptible only to amikacin,
fosfomycin, and tigecycline. Recently, an NDM-5- and
mcr-1-producing E. coli has been recovered in the USA,
but, still, several drugs were active against that organism
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including amikacin, gentamicin, aztreonam, and
nitrofurantoin [27]. In China, some cases of K. pneumoniae
isolates co-producing mcr-1 and NDM-5 have also been re-
ported [9]. An association of mcr-1, blaNDM-9, and fosA3
genes has also be reported in E. coli strains from chicken
products, exhibiting high level of resistance to colistin [28].
The mcr-1 gene has been found in KPC-producing and
carbapenem-resistant K. pneumonia isolates in Italy and
Greece as well.
Overall, the occurrence of such multidrug-resistant entero-
bacterial isolates underscores the importance of this major
emerging problem and highlights that care needs to be taken
to prevent further dissemination. However, recent studies
showed that the occurrence ofmcr-producing isolates remains
relatively low in many countries. For instance, a very low
prevalence of mcr-1 and mcr-1 producers was found in
Switzerland among enterobacterial isolates recovered from
urinary tract infections [29]. Similarly, no mcr-1-producing
enterobacterial isolate was identified when screening a large
collection of enterobacterial isolates recovered from bacter-
emia in the same country [30]. A significant increase in the
detection of colistin resistance has been observed in isolates
[22]: up to 50% of E. coli isolated from swine with diarrhea or
edema were mcr-1-positive. A high frequency of mcr-1-posi-
tive E. coli has been seen in livestock and food isolates, main-
ly in turkey (10.7 %) and broilers (5.6 %) in Germany [4].
Variants of the mcr-1 gene have been identified, with mcr-2
reported by Xavier et al. [31] in Belgium from porcine and
bovine samples, and mcr-1.2 by Di Pilato in Italy in
K. pneumoniae [32].
Clinical consequences and medical needs
Continued spread of the plasmid-borne mcr-1 gene will com-
promise the clinical utility of last-resort polymyxins, which may
lead tomore frequent treatment failure and substantial additional
morbidity and mortality. If establishing itself in successful pan-
demic clones such as E. coli ST131 or K. pneumoniae
ST11/ST258, acquisition of mcr-1 will likely lead to the global
presence of pan-drug-resistant pathogens. Consequently, the
European Medicines Agency (EMA), in response to a
European Commission request, is currently updating the clinical
guidelines on the use of colistin. The EMA is considering to
upgrade colistin as an antibiotic of category 2, dedicated to
critical medicine and to be used only if no alternatives actually
exist. TheWorld Health Organization (WHO) already considers
colistin of crucial importance in human medicine (http://who.
int/iris/bitstream/10665/77376/1/9789241504485_eng.pdf).
The European Centre for Disease Prevention and Control
(ECDC) recently released a medical risk assessment on
plasmid-mediated colistin resistance in Enterobacteriaceae
(ECDC rapid risk assessment. Plasmid-mediated colistin
resistance in Enterobacteriaceae, June 13th, 2016; http://www.
ecdc.europa.eu). The document describes a short series of
specific actions to help reduce colonization and infection risks:
& Develop improved laboratory methods for colistin AST
and molecular mcr-1 detection. Microbroth dilution is
the recommended reference method, while several diag-
nostic PCR tests have already been described.
& Implement integrated surveillance in hospitals, the com-
munity, food, animals, and environment (the One Health
approach).
& Screening of multidrug-resistant enterobacterial isolates
from patients who recently visited healthcare facilities in
foreign countries.
& Perform targeted surveillance to detect reservoirs and in-
clude individuals who underwent selective decontamina-
tion of the gastrointestinal tract using polymyxins [1].
& Carefully manage patients infected with colistin-resistant
strains and reinforce infection prevention and control mea-
sures [33].
& Assure that colistin treatment is always accompanied by
adequate AST of clinical isolates.
& Apply prudent antimicrobial therapy [17, 34] and screen-
ing for carriage at hospital admission [35, 36].
Recommendations
Various pragmatic aspects must be considered to help improve
the current diagnostic and clinical needs:
The use of selective culture media as an initial screening
tool Culture media are well accepted in clinical microbiology
and quite well available and affordable on a worldwide scale.
The development of novel selective (and possibly chromogen-
ic) culture media will facilitate screening for colonization or
infection of high-risk patients: those previously hospitalized,
those hospitalized in endemic zones, those with a known his-
tory of infection or colonization with colistin-resistant bacte-
ria, or those who were recently exposed to antibiotics. One
needs to keep in mind that future work might establish if
hospitalization is, indeed, the most significant risk factor
since, even to date, several community cases have already
been reported. This will eventually help to implement appro-
priate infection control measures [37, 38]. Such screening
should include patients who were previously subjected to
colistin-based decolonization [1].
Besides the potential use in human medicine, selective cul-
ture media are also relevant to veterinary surveillance consid-
ering that screening may soon become a regulatory require-
ment (e.g., screening of fecal samples from livestock), as part
of the ongoing monitoring programs for antibiotic resistance
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in bacteria from animals (http://www.healthcanal.
com/infections). To date, the exact prevalence of the mcr-1
gene remains unknown. Benefits of culture-based polymyxin
resistance screening and rapid detection of polymyxin resis-
tance in Enterobacteriaceae have been pointed out [39, 40]. To
render the search for colistin resistance more clinically useful,
simultaneous detection of carbapenem resistance should be
considered. A suitable culture medium facilitating such a com-
bined diagnosis could be of significant relevance in countries
facing coinciding and possibly extensive spread of carbapen-
em resistance.
The recently developed Super Polymyxin selective medi-
um provides a useful tool for the screening of polymyxin-
resistant Gram-negative isolates [39]. Using a large collection
of polymyxin-resistant isolates, it has been shown to possess
close to 100 % sensitivity and specificity. Noteworthy, it may
detect both intrinsic and acquired polymyxin resistance, either
using replicates of isolated colonies or even direct stool or
rectal swabs samples, depending on local surveillance needs.
Disk diffusion assays, antibiotic gradient testing, and au-
tomated AST Disk diffusion methods are not appropriate for
the sensitive and specific detection of colistin resistance and,
hence, there needs to be a specific search for alternative, fast,
reproducible, and, to date, preferably culture-based AST
methods. The same problem holds true for gradient testing
(e.g., the Etest, which is available in research-use-only format
for colistin), which seems to underestimate resistance levels,
following evaluation studies conducted by the EUCAST.
Currently, only BMD methods are recommended as reliable
tests for colistin resistance. However, this method is quite
cumbersome and labor-intensive to perform. A reliable colis-
tin MIC test is of utmost importance for patient management,
since colistin is a drug with significant adverse effects, which
requires precise therapeutic drug monitoring (TDM) to avoid
toxic effects while maintaining sufficient antibacterial activity.
In addition, precise assessment of serum dosage is important
as well, and dosing needs to be compatible with the MIC(s) of
the infecting strain(s). Innovative propositions for rapid
culture-based testing are still urgently needed. In order to in-
crease the throughput, precision, and speed of colistin resis-
tance testing, it would be good if (additional) assays for the
commercially available automated AST systems could be de-
veloped or improved. The recently developed Rapid
Polymyxin NP test is a tool that is available for accurate dis-
tinction between susceptible or resistant strains [39]. It may be
implemented worldwide and is affordable. Results are obtain-
ed in less than 4 h and both specificity and susceptibility are
high. This colorimetric test may be used for testing colonies
and positive blood cultures, therefore providing an interesting
tool for the rapid implementation of adequate therapies in the
context of bacteremia and sepsis [40]. The interest in rapid
confirmation of polymyxin resistance using phenotypic tests
has been highlighted by Jayol et al. [41], especially if it can be
done directly from blood culture broth in a few hours and
enable early adaptation of antimicrobial therapy in case of
multidrug resistance.
Molecular diagnostics Matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry (MALDI-TOF
MS) can be used for specific protein molecule detection.
Currently, however, there is no such test that would directly
detect and/or identify the MCR-1 protein, but such tests might
be developed, especially if more advancedMSmethods could
be used. Assays to detect the mcr-1 enzymatic activities un-
derlying the resistance or direct detection of the modified LPS
molecules might also become interesting options with the pro-
gression of MS technology. This may, in the end, still remain
difficult to implement diagnostically, since resistance may de-
pend upon rather subtle up- or down-regulation of LPS-
modifying enzymes.
Molecular biological detection of the acquired mcr-like
genes at the nucleic acid level is relatively easy and can be
done with simple and straightforward PCR tests, either devel-
oped in-house or being part of FDA-approved approaches.
Rapid real-time PCR techniques have recently been devel-
oped for that purpose and validated using not only pure bac-
terial cultures, but also stool samples [42, 43]. Such tests could
be easily added to existing multiplex panels, usually in addi-
tion to genes encoding other key resistance mechanisms.
Nevertheless, it is noteworthy that several polymyxin resis-
tance mechanisms are chromosomally encoded and depend
upon the substitution of amino acids in diverse regulatory
proteins involved in LPS biosynthesis. Therefore, a single
PCR approach alone cannot be an adequate tool for an overall
diagnosis due to the high diversity of sometimes even co-
existing resistance mechanisms. Not only is subsequent se-
quencing required, but the issue is that correlating amino acid
substitutions to corresponding susceptibility or resistance
changes (and, hence, distinct MIC values) remains almost
impossible.
Conclusion
Colistin resistance poses a universal problem and rapid detec-
tion of the pheno- or genotype is of core importance.
Phenotyping would initially be preferred given the diverse,
potentially co-existing and complex resistance mechanisms,
and since phenotyping takes into account features that are hard
to detect by alternative, usually proteomic, genetic, or geno-
mic methodologies [44]. This short review focused on pheno-
typing, since the many alternative test formats that do exist at
the proof of principle level do not (yet) meet quality and val-
idation requirements as imposed by the FDA and other regu-
latory agencies. Hence, the development of innovative,
4
htt
p:/
/do
c.r
ero
.ch
accurate, and rapid tests, although clinically very important,
remains quite challenging in the context of polymyxin resis-
tance, owing to the diversity and complexity of the mecha-
nisms involved. Molecular tests cannot be reliably implement-
ed as long as a careful assessment of the correlation between
phenotype and genotype has been accurately and precisely
performed. This underscores the necessity to reinforce the
current fundamental investigations aiming to exactly decipher
the fundamental polymyxin resistance mechanisms and their
genetic and proteomic bases.
In fact, the renewed interest in polymyxins observed to date
reinforces the need to better evaluate the local and internation-
al frequency of occurrence of polymyxin-resistant strains, re-
gardless of the underlying resistance mechanisms, whether
plasmid or chromosomally encoded. The recent identification
in France of a major outbreak caused by OXA-48-producing
and colistin-resistant K. pneumoniae strongly underscores the
relevance of suchmonitoring [45] and urges toward a real One
Health approach investigating not only human infections and
colonization, but including research of food, the environment,
and animal reservoirs. Finally, the recent observation that co-
listin resistance may emerge as a consequence of chlorhexi-
dine use [46] again demonstrates the complexity of antibiotic
resistance and the need for concerted actions towards the op-
timal use of antibiotics and antiseptics.
References
1. Rawson TM, Moore LS, Hatcher JC, Donaldson H, Holmes AH
(2016) Plasmid-mediated colistin resistance mechanisms: is it time
to revise our approach to selective digestive decontamination?
Lancet Infect Dis 16:149–150
2. Castanheira M, Griffin MA, Deshpande LM, Mendes RE, Jones
RN, Flamm RK (2016) Detection ofmcr-1 among Escherichia coli
clinical isolates collected worldwide as part of the SENTRY
Antimicrobial Surveillance Program in 2014 and 2015.
Antimicrob Agents Chemother 60:5623–5624
3. Agersø Y, Torpdahl M, Zachariasen C, Seyfarth A, Hammerum
AM, Nielsen EM (2012) Tentative colistin epidemiological cut-
off value for Salmonella spp. Foodborne Pathog Dis 9:367–369
4. Irrgang A, Roschanski N, Tenhagen BA, Grobbel M,
Skladnikiewicz-Ziemer T, Thomas K, Roesler U, Käsbohrer A
(2016) Prevalence of mcr-1 in E. coli from livestock and food in
Germany, 2010–2015. PLoS One 11, e0159863
5. Beceiro A,Moreno A, Fernández N, Vallejo JA, Aranda J, Adler B,
Harper M, Boyce JD, Bou G (2014) Biological cost of different
mechanisms of colistin resistance and their impact on virulence in
Acinetobacter baumannii. Antimicrob Agents Chemother 58:518–
526
6. Olaitan AO, Morand S, Rolain JM (2014) Mechanisms of poly-
myxin resistance: acquired and intrinsic resistance in bacteria.
Front Microbiol 5:643
7. Jansen G, Mahrt N, Tueffers L, Barbosa C, Harjes M, Adolph G,
Friedrichs A, Krenz-Weinreich A, Rosenstiel P, Schulenburg H
(2016) Association between clinical antibiotic resistance and
susceptibility of Pseudomonas in the cystic fibrosis lung. Evol
Med Public Health 2016:182–194
8. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y,
Tian G, Dong B, Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He
D, Zhou H, Liang Z, Liu JH, Shen J (2016) Emergence of plasmid-
mediated colistin resistance mechanismMCR-1 in animals and hu-
man beings in China: a microbiological and molecular biological
study. Lancet Infect Dis 16:161–168
9. Du H, Chen L, Tang YW, Kreiswirth BN (2016) Emergence of the
mcr-1 colistin resistance gene in carbapenem-resistant
Enterobacteriaceae. Lancet Infect Dis 16:287–288
10. Jain A, Hopkins KL, Turton J, Doumith M, Hill R, Loy R,Meunier
D, Pike R, Livermore DM, Woodford N (2014) NDM
carbapenemases in the United Kingdom: an analysis of the first
250 cases. J Antimicrob Chemother 69:1777–1784
11. Giani T, Arena F, Vaggelli G, Conte V, Chiarelli A, Henrici De
Angelis L, Fornaini R, Grazzini M, Niccolini F, Pecile P,
Rossolini GM (2015) Large nosocomial outbreak of colistin-resis-
tant, carbapenemase-producing Klebsiella pneumoniae traced to
clonal expansion of an mgrB deletion mutant. J Clin Microbiol
53:3341–3344
12. Webb HE, Granier SA, Marault M, Millemann Y, den Bakker HC,
Nightingale KK, Bugarel M, Ison SA, Scott HM, Loneragan GH
(2016) Dissemination of the mcr-1 colistin resistance gene. Lancet
Infect Dis 16:144–145
13. Haenni M, Poirel L, Kieffer N, Châtre P, Saras E, Métayer V,
Dumoulin R, Nordmann P, Madec JY (2016) Co-occurrence of
extended spectrum β lactamase and MCR-1 encoding genes on
plasmids. Lancet Infect Dis 16:281–282
14. Figueiredo R, Henriques A, Sereno R, Mendonça N, da Silva GJ
(2015) Antimicrobial resistance and extended-spectrum β-
lactamases of Salmonella enterica serotypes isolated from livestock
and processed food in Portugal: an update. Foodborne Pathog Dis
12:110–117
15. Olaitan AO, Thongmalayvong B, Akkhavong K, Somphavong S,
Paboriboune P, Khounsy S, Morand S, Rolain JM (2015) Clonal
transmission of a colistin-resistant Escherichia coli from a domes-
ticated pig to a human in Laos. J Antimicrob Chemother 70:3402–
3404
16. Olaitan AO, Chabou S, Okdah L, Morand S, Rolain JM (2016)
Dissemination of the mcr-1 colistin resistance gene. Lancet Infect
Dis 16:147
17. Olaitan AO, Morand S, Rolain JM (2016) Emergence of colistin-
resistant bacteria in humans without colistin usage: a newworry and
cause for vigilance. Int J Antimicrob Agents 47:1–3
18. Falgenhauer L, Waezsada SE, Yao Y, Imirzalioglu C, Käsbohrer A,
Roesler U, Michael GB, Schwarz S, Werner G, Kreienbrock L,
Chakraborty T, RESET consortium (2016) Colistin resistance gene
mcr-1 in extended-spectrum β-lactamase-producing and
carbapenemase-producing Gram-negative bacteria in Germany.
Lancet Infect Dis 16:282–283
19. Poirel L, Kieffer N, Liassine N, Thanh D, Nordmann P (2016)
Plasmid-mediated carbapenem and colistin resistance in a clinical
isolate of Escherichia coli. Lancet Infect Dis 16:281
20. Poirel L, Hombrouck-Alet C, Freneaux C, Bernabeu S, Nordmann
P (2010) Global spread of New Delhi metallo-β-lactamase 1.
Lancet Infect Dis 10:832
21. Malhotra-Kumar S, Xavier BB, Das AJ, Lammens C, Hoang HT,
Pham NT, Goossens H (2016) Colistin-resistant Escherichia coli
harbouring mcr-1 isolated from food animals in Hanoi, Vietnam.
Lancet Infect Dis 16:286–287
22. Kusumoto M, Ogura Y, Gotoh Y, Iwata T, Hayashi T, Akiba M
(2016) Colistin-resistant mcr-1-positive pathogenic Escherichia
coli in swine, Japan, 2007–2014. Emerg Infect Dis 22:1315–1317
23. Arcilla MS, van Hattem JM, Matamoros S, Melles DC, Penders J,
de Jong MD, Schultsz C; COMBAT consortium (2016)
5
htt
p:/
/do
c.r
ero
.ch
Dissemination of the mcr-1 colistin resistance gene. Lancet Infect
Dis 16:147–149
24. Prim N, Rivera A, Rodríguez-Navarro J, Español M, Turbau M,
Coll P, Mirelis B (2016) Detection ofmcr-1 colistin resistance gene
in polyclonal Escherichia coli isolates in Barcelona, Spain, 2012 to
2015. Euro Surveill 21(13)
25. Hasman H, Hammerum AM, Hansen F, Hendriksen RS, Olesen B,
Agersø Y, Zankari E, Leekitcharoenphon P, Stegger M, Kaas RS,
Cavaco LM, Hansen DS, Aarestrup FM, Skov RL (2015) Detection
of mcr-1 encoding plasmid-mediated colistin-resistant Escherichia
coli isolates from human bloodstream infection and imported chick-
en meat, Denmark 2015. Euro Surveill 20(49)
26. Kluytmans-van den Bergh MF, Huizinga P, Bonten MJ, Bos M, De
Bruyne K, Friedrich AW, Rossen JW, Savelkoul PH, Kluytmans JA
(2016) Presence of mcr-1-positive Enterobacteriaceae in retail
chicken meat but not in humans in the Netherlands since 2009.
Euro Surveill 21(9)
27. Mediavilla JR, Patrawalla A, Chen L, Chavda KD, Mathema B,
Vinnard C, Dever LL, Kreiswirth BN (2016) Colistin- and
carbapenem-resistant Escherichia coli harboring mcr-1 and
blaNDM-5, causing a complicated urinary tract infection in a patient
from the United States. MBio 7, e01191-16
28. Yao X, Doi Y, Zeng L, Lv L, Liu JH (2016) Carbapenem-resistant
and colistin-resistant Escherichia coli co-producing NDM-9 and
MCR-1. Lancet Infect Dis 16:288–289
29. Liassine N, Assouvie L, Descombes MC, Tendon VD, Kieffer N,
Poirel L, Nordmann P (2016) Very low prevalence of MCR-1/
MCR-2 plasmid-mediated colistin resistance in urinary tract
Enterobacteriaceae in Switzerland. Int J Infect Dis 51:4–5
30. Nordmann P, Assouvie L, Prod’Hom G, Poirel L, Greub G (2016)
Screening of plasmid-mediated MCR-1 colistin-resistance from
bacteremia. Eur J Clin Microbiol Infect Dis 35(11):1891–1892
31. Xavier BB, Lammens C, Ruhal R, Kumar-Singh S, Butaye P,
Goossens H, Malhotra-Kumar S (2016) Identification of a novel
plasmid-mediated colistin-resistance gene, mcr-2, in Escherichia
coli, Belgium, June 2016. Euro Surveill 21(27)
32. Di Pilato V, Arena F, Tascini C, Cannatelli A, Henrici DeAngelis L,
Fortunato S, Giani T, Menichetti F, Rossolini GM (2016)mcr-1.2, a
new mcr variant carried on a transferable plasmid from a colistin-
resistant KPC carbapenemase-producing Klebsiella pneumoniae
strain of sequence type 512. Antimicrob Agents Chemother 60:
5612–5615
33. Nordmann P, Poirel L (2016) Plasmid-mediated colistin resistance: an
additional antibiotic resistance menace. ClinMicrobiol Infect 22:398–
400
34. van Duin D, Doi Y (2015) Outbreak of colistin-resistant,
carbapenemase-producing Klebsiella pneumoniae: are we at the
end of the road? J Clin Microbiol 53:3116–3117
35. Gray JW, Mahida N (2016) How do you solve a problem like
multidrug-resistant Gram-negative bacteria? J Hosp Infect 92:1–2
36. Skov RL, Monnet DL (2016) Plasmid-mediated colistin resistance
(mcr-1 gene): three months later, the story unfolds. Euro Surveill
21(9)
37. McGann P, Snesrud E, Maybank R, Corey B, Ong AC, Clifford R,
Hinkle M, Whitman T, Lesho E, Schaecher KE (2016) Escherichia
coli harboring mcr-1 and blaCTX-M on a novel IncF plasmid: first
report ofmcr-1 in the United States. Antimicrob Agents Chemother
60:4420–4421
38. YuH, Qu F, Shan B,Huang B, JiaW, Chen C, Li A,MiaoM, Zhang
X, Bao C, Xu Y, Chavda KD, Tang YW, Kreiswirth BN, Du H,
Chen L (2016) Detection of the mcr-1 colistin resistance gene in
carbapenem-resistant Enterobacteriaceae from different hospitals in
China. Antimicrob Agents Chemother 60:5033–5035
39. Nordmann P, Jayol A, Poirel L (2016) Rapid detection of polymyxin
resistance in Enterobacteriaceae. Emerg Infect Dis 22:1038–1043
40. Nordmann P, Jayol A, Poirel L (2016) A universal culture medium
for screening polymyxin-resistant Gram-negative isolates. J Clin
Microbiol 54:1395–1399
41. Jayol A, Dubois V, Poirel L, Nordmann P (2016) Rapid detection of
polymyxin-resistant Enterobacteriaceae from blood cultures. J Clin
Microbiol 54:2273–2277
42. Bontron S, Poirel L, Nordmann P (2016) Real-time PCR for detec-
tion of plasmid-mediated polymyxin resistance (mcr-1) from cul-
tured bacteria and stools. J Antimicrob Chemother 71:2318–2320
43. Nijhuis RH, Veldman KT, Schelfaut J, Van Essen-Zandbergen A,
Wessels E, Claas EC, Gooskens J (2016) Detection of the plasmid-
mediated colistin-resistance genemcr-1 in clinical isolates and stool
specimens obtained from hospitalized patients using a newly devel-
oped real-time PCR assay. J Antimicrob Chemother 71:2344–2346
44. Schwarz S, Johnson AP (2016) Transferable resistance to colistin: a
new but old threat. J Antimicrob Chemother 71:2066–2070
45. Jayol A, Poirel L, Dortet L, Nordmann P (2016) National survey of
col is t in res is tance among carbapenemase-producing
Enterobacteriaceae and outbreak caused by colistin-resistant
OXA-48-producing Klebsiella pneumoniae, France, 2014. Euro
Surveill 21:(37)
46. WandME, Bock LJ, Bonney LC, Sutton JM (2016)Mechanisms of
increased resistance to chlorhexidine and cross-resistance to colistin
following exposure of Klebsiella pneumoniae clinical isolates to
chlorhexidine. Antimicrob Agents Chemother (in press)
6
htt
p:/
/do
c.r
ero
.ch
